Santaris Pharma A/S, which on Wednesday announced an agreement to share some of its technology with BetaIsarna Therapeutics GmbH, has announced another agreement with GlaxoSmithKline (NYSE: GSK).
Pursuant to the agreement, GSK will gain access to Santaris' Locked Nucleic Acid technology to develop RNA-targeted medicines. GSK will be able to obtain rights to utilize Santaris Pharma's proprietary LNA Drug Platform to research, develop and commercialize LNA-medicines targeted against up to three targets.
Financial details on the deal were not disclosed.
"We are delighted to do this new deal with GSK," Dr. Henrik Oerum, chief scientific officer and vice president of business development for Santaris Pharma, said. "This is the sixth partner deal we have concluded in the past 12 months with pharmaceutical and biotech companies, so it has really been a spectacular year for Santaris Pharma."
Santaris, which was founded in Denmark and has a facility in San Diego, says its LNA drug platform overcomes the limitations of earlier technologies through a combination of small size and high affinity, which it says allows the new class of drug candidates to inhibit RNA targets in many different tissues without the need for complex delivery vehicles. The company's research and development activities focus on cardiometabolic disorders, infectious and inflammatory diseases, cancers and rare genetic disorders.